182 related articles for article (PubMed ID: 36768790)
1. Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma.
Mühle C; Kornhuber J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768790
[TBL] [Abstract][Full Text] [Related]
2. Biochemical identification of a neutral sphingomyelinase 1 (NSM1)-like enzyme as the major NSM activity in the DT40 B-cell line: absence of a role in the apoptotic response to endoplasmic reticulum stress.
Fensome AC; Josephs M; Katan M; Rodrigues-Lima F
Biochem J; 2002 Jul; 365(Pt 1):69-77. PubMed ID: 12071841
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipids in psychiatric disorders and pain syndromes.
Mühle C; Reichel M; Gulbins E; Kornhuber J
Handb Exp Pharmacol; 2013; (216):431-56. PubMed ID: 23563670
[TBL] [Abstract][Full Text] [Related]
4. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.
Becker KA; Riethmüller J; Lüth A; Döring G; Kleuser B; Gulbins E
Am J Respir Cell Mol Biol; 2010 Jun; 42(6):716-24. PubMed ID: 19635928
[TBL] [Abstract][Full Text] [Related]
5. Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis.
Leurs CE; Lopes Pinheiro MA; Wierts L; den Hoedt S; Mulder MT; Eijlers AJC; Schoonheim MM; Balk LJ; Uitdehaag BMJ; Killestein J; de Vries HE
Mult Scler Relat Disord; 2019 Feb; 28():44-49. PubMed ID: 30553168
[TBL] [Abstract][Full Text] [Related]
6. The role of acid sphingomyelinase and modulation of sphingolipid metabolism in bacterial infection.
Simonis A; Schubert-Unkmeir A
Biol Chem; 2018 Sep; 399(10):1135-1146. PubMed ID: 29924727
[TBL] [Abstract][Full Text] [Related]
7. Physiological functions and therapeutic applications of neutral sphingomyelinase and acid sphingomyelinase.
Xiang H; Jin S; Tan F; Xu Y; Lu Y; Wu T
Biomed Pharmacother; 2021 Jul; 139():111610. PubMed ID: 33957567
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of acid sphingomyelinase and neutral sphingomyelinase-2 inversely determines the cellular resistance to plasmalemmal injury by pore-forming toxins.
Schoenauer R; Larpin Y; Babiychuk EB; Drücker P; Babiychuk VS; Avota E; Schneider-Schaulies S; Schumacher F; Kleuser B; Köffel R; Draeger A
FASEB J; 2019 Jan; 33(1):275-285. PubMed ID: 29979630
[TBL] [Abstract][Full Text] [Related]
9. Content and structure of ceramide and sphingomyelin and sphingomyelinase activity in mouse hepatoma-22.
Rylova SN; Somova OG; Zubova ES; Dudnik LB; Kogtev LS; Kozlov AM; Alesenko AV; Dyatlovitskaya EV
Biochemistry (Mosc); 1999 Apr; 64(4):437-41. PubMed ID: 10231598
[TBL] [Abstract][Full Text] [Related]
10. Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway.
Levade T; Vidal F; Vermeersch S; Andrieu N; Gatt S; Salvayre R
Biochim Biophys Acta; 1995 Oct; 1258(3):277-87. PubMed ID: 7548198
[TBL] [Abstract][Full Text] [Related]
11. Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies.
Abusukhun M; Winkler MS; Pöhlmann S; Moerer O; Meissner K; Tampe B; Hofmann-Winkler H; Bauer M; Gräler MH; Claus RA
Front Immunol; 2021; 12():784989. PubMed ID: 34987511
[TBL] [Abstract][Full Text] [Related]
12. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis.
Schmuth M; Man MQ; Weber F; Gao W; Feingold KR; Fritsch P; Elias PM; Holleran WM
J Invest Dermatol; 2000 Sep; 115(3):459-66. PubMed ID: 10951284
[TBL] [Abstract][Full Text] [Related]
13. Alterations of plasma glycerophospholipid and sphingolipid species in male alcohol-dependent patients.
Reichel M; Hönig S; Liebisch G; Lüth A; Kleuser B; Gulbins E; Schmitz G; Kornhuber J
Biochim Biophys Acta; 2015 Nov; 1851(11):1501-10. PubMed ID: 26291032
[TBL] [Abstract][Full Text] [Related]
14. Formation of free fatty acid and ceramide during brain handling: lability of sphingomyelin.
Deshmukh GD; Radin NS
J Neurochem; 1985 Apr; 44(4):1152-5. PubMed ID: 2983027
[TBL] [Abstract][Full Text] [Related]
15. Plasma Sphingolipid Profile of Healthy Black and White Adults Differs Based on Their Parental History of Type 2 Diabetes.
Mandal N; Stentz F; Asuzu PC; Nyenwe E; Wan J; Dagogo-Jack S
J Clin Endocrinol Metab; 2024 Feb; 109(3):740-749. PubMed ID: 37804534
[TBL] [Abstract][Full Text] [Related]
16. Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats.
Pérez-Villavicencio R; Flores-Estrada J; Franco M; Escalante B; Pérez-Méndez O; Mercado A; Bautista-Pérez R
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270028
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Acid Sphingomyelinase Activity Is Associated with Biomarkers and Phenotypes of Alcohol Use and Dependence in Patients and Healthy Controls.
Mühle C; Weinland C; Gulbins E; Lenz B; Kornhuber J
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30551571
[TBL] [Abstract][Full Text] [Related]
18. Methods to Characterize Synthesis and Degradation of Sphingomyelin at the Plasma Membrane and Its Impact on Lipid Raft Dynamics.
Nikolova-Karakashian M
Methods Mol Biol; 2021; 2187():113-129. PubMed ID: 32770504
[TBL] [Abstract][Full Text] [Related]
19. Sphingomyelinase and cell-permeable ceramide analogs stimulate cellular proliferation in quiescent Swiss 3T3 fibroblasts.
Olivera A; Buckley NE; Spiegel S
J Biol Chem; 1992 Dec; 267(36):26121-7. PubMed ID: 1464623
[TBL] [Abstract][Full Text] [Related]
20. Preparation of fluorescence-labeled GM1 and sphingomyelin by the reverse hydrolysis reaction of sphingolipid ceramide N-deacylase as substrates for assay of sphingolipid-degrading enzymes and for detection of sphingolipid-binding proteins.
Nakagawa T; Tani M; Kita K; Ito M
J Biochem; 1999 Sep; 126(3):604-11. PubMed ID: 10467178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
